Evidence map›Paper›PMID 39779221›Full record

ArticleAlcohol, clinical & experimental research2025

Harmonization of alcohol use data and mortality across a multi-national HIV cohort collaboration.

Suzanne M Ingle, Adam Trickey, Anastasia Lankina, Kathleen A McGinnis, Amy Justice, Matthias Cavassini, Antonella d' Arminio Monforte, Ard van Sighem, M John Gill, Heidi M Crane and 12 more

Abstract read
In one paragraph

Article in Alcohol, clinical & experimental research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Suzanne M InglePopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.ORCID https://orcid.org/0000-0003-3057-6636
Adam TrickeyPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Anastasia LankinaInstitute of Immunity and Transplantation, UCL, London, UK.
Kathleen A McGinnisUS Department of Veteran Affairs, West Haven, Connecticut, USA.
Amy JusticeVA Connecticut Healthcare System, West Haven, Connecticut, USA.ORCID https://orcid.org/0000-0003-0139-5502
Matthias CavassiniService of Infectious Diseases, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Antonella d' Arminio MonforteICONA Foundation, Milan, Italy.
Ard van SighemStichting HIV Monitoring, Amsterdam, The Netherlands.ORCID https://orcid.org/0000-0002-6656-0516
M John GillDivision of Infectious Diseases, University of Calgary, Calgary, Alberta, Canada.
Heidi M CraneDepartment of Medicine, University of Washington, Seattle, Washington, USA.
Niels ObelRigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Inma JarrinNational Centre of Epidemiology, Carlos III Health Institute, Madrid, Spain.
Elmar WallnerLandeskrankenhaus Graz II, Standort West, Graz, Austria.
Jodie GuestDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.
Michael J SilverbergDivision of Research, Kaiser Permanente Northern California, Pleasanton, California, USA.ORCID https://orcid.org/0000-0001-9322-1395
Georgia VourliSchool of Medicine, University of Athens, Athens, Greece.
Linda WittkopUniv. Bordeaux, INSERM, Institut Bergonié, BPH, U1219, CIC-EC 1401, Bordeaux, France.
Timothy R SterlingSchool of Medicine, Vanderbilt University, Nashville, Tennessee, USA.
Derek D SatreDivision of Research, Kaiser Permanente Northern California, Pleasanton, California, USA.
Greer A BurkholderDivision of Infectious Diseases, University of Alabama, Birmingham, Alabama, USA.
Dominique CostagliolaSorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Paris, France.
Jonathan A C SternePopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

Funding

University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI CONNIE L CELUM · 1988 to 2026
$104.9M
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
2/3 COMpAAAS Tripartite: ART-CC, KP, and VAU01AA026230 · NIAAA · KAISER FOUNDATION RESEARCH INSTITUTE · PI SATRE, DEREK D, SILVERBERG, MICHAEL J · 2017 to 2021
$3.0M
3/3 COMpAAAS Tripartite: ART-CC, KP, and VAU01AA026224 · NIAAA · YALE UNIVERSITY · PI JUSTICE, AMY CAROLINE · 2017 to 2021
$2.9M
1/3 Collaborative Research in HIV/AIDS, Alcohol, and Related Comorbidities (COMpAAAS) Tripartite: ART-CC, KP, and VAU01AA026209 · NIAAA · UNIVERSITY OF BRISTOL · PI STERNE, JONATHAN · 2017 to 2021
$2.2M
Mentoring alcohol use intervention research in HIV health care settingsK24AA025703 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Derek D Satre · 2018 to 2026
$1.8M
Alberta HealthANRS-MIE (Maladies Infectieuses Emergentes)Austrian Agency for Health and Food Safety (AGES)Bristol-Myers SquibbCFAR Network of Integrated Clinical SystemsDutch Ministry of Health, Welfare and SportFondo Europeo de Desarrollo Regional (FEDER)French Ministry of HealthGerman Centre for Infection Research NCT02149004GileadInstitut National de la Santé et de la Recherche Médicale (INSERM)Instituto de Salud Carlos III through the Red Temática de Investigación Cooperativa en Sida RD06/006Instituto de Salud Carlos III through the Red Temática de Investigación Cooperativa en Sida RD12/0017/0018Instituto de Salud Carlos III through the Red Temática de Investigación Cooperativa en Sida RD16/0002/0006ISCIII-Subdirección General de EvaluaciónJanssen PharmaceuticaMerck Sharp and DohmeNational Institute for Health Research NF-SI-0611-10168NCATS NIH HHS UL1 TR001863NIAAA NIH HHS K24 AA025703NIAAA NIH HHS U01 AA026209NIAAA NIH HHS U01-AA026209NIAAA NIH HHS U01 AA026224NIAAA NIH HHS U01-AA026224NIAAA NIH HHS U01 AA026230NIAAA NIH HHS U01-AA026230NIAID NIH HHS P30 AI027757Preben og Anna Simonsens FondSpanish Ministry of Healththe Swiss National Science FoundationUS Department of Veterans AffairsUS National Institute of Allergy and Infectious DiseasesVHA Office of Research and DevelopmentViiV HealthcareWellcome TrustWellcome Trust 222770/Z/21/Z
6 · The paper itself

Abstract

backgroundAlcohol use is measured in diverse ways across settings. Harmonization of measures is necessary to assess effects of alcohol use in multi-cohort collaborations, such as studies of people with HIV (PWH).

methodsData were combined from 14 HIV cohort studies (nine European, five North American) participating in the Antiretroviral Therapy Cohort Collaboration. We analyzed data on adult PWH with measured alcohol use at any time from 6 months before starting antiretroviral therapy. Five cohorts measured alcohol use with AUDIT-C and others used cohort-specific measures. We harmonized alcohol use as grams/day, calculated using country-level definitions of a standard drink. For Alcohol Use Disorders Identification Test (AUDIT-C), we used Items 1 (frequency) and 2 (number of drinks on a typical day). Where alcohol was measured in categories, we used the mid-point to calculate grams/day. We used multivariable Cox models to estimate associations of alcohol use with mortality.

resultsAlcohol use data were available for 83,424 PWH, 22,447 (27%) had AUDIT-C measures and 60,977 (73%) recorded the number of drinks/units per week/day. Of the sample, 19,150 (23%) were female, 54,006 (65%) had White ethnicity, and median age was 42 years. Median alcohol use was 0.3 g/day (interquartile range [IQR] 0-4.8) and 0 g/day (IQR 0-20) for those with and without AUDIT-C. There was a J-shaped relationship between grams/day and mortality, with higher mortality for PWH reporting no alcohol use (adjusted hazard ratio [aHR] 1.46; 95% CI: 1.23-1.72) and heavier (>61.0 g/day) alcohol use (aHR 1.92; 1.41-2.59) compared with 0.1-5.5 g/day among those with AUDIT-C measures. Associations were similar among those with non-AUDIT-C measures.

conclusionsGrams/day is a useful metric to harmonize diverse measures of alcohol use. Magnitudes of associations of alcohol use with mortality may differ by setting and measurement method. Higher mortality among those with heavier alcohol use strengthens the case for interventions to reduce drinking.

Indexed as

alcoholAUDIT‐CepidemiologyharmonizationHIV

Identifiers

PMID39779221
PMCPMC11828971

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.